Valneva (NASDAQ:VALN - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Valneva has set its FY 2024 guidance at EPS.
Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.02. The firm had revenue of $40.97 million during the quarter, compared to the consensus estimate of $46.83 million. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%.
Valneva Price Performance
Shares of VALN traded down $0.07 during mid-day trading on Tuesday, reaching $5.78. 15,279 shares of the stock traded hands, compared to its average volume of 11,667. The company has a current ratio of 2.63, a quick ratio of 2.15 and a debt-to-equity ratio of 0.97. Valneva has a 1 year low of $5.40 and a 1 year high of $14.49. The company has a market cap of $469.63 million, a price-to-earnings ratio of -11.12 and a beta of 2.17. The firm has a fifty day moving average price of $6.23 and a 200 day moving average price of $7.18.
Analyst Upgrades and Downgrades
Separately, HC Wainwright decreased their target price on Valneva from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, October 11th.
View Our Latest Stock Analysis on Valneva
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
